English name: Sorafenib
[otw_shortcode_tabslayout tabs=”9″ tab_1_title=”Overview” tab_1_content=”Sorafenib is a new oral antitumor drug that inhibits tumor cells, blood vessel growth, and formation.” tab_2_title=”Indications” tab_2_content=”1. For the treatment of inoperable advanced renal cell carcinoma. 2. for the treatment of inoperable or distant metastatic hepatocellular carcinoma. 3. for the treatment of locally recurrent or metastatic progressive radioiodine-refractory differentiated thyroid cancer.” tab_3_title=”Dosage” tab_3_content=”400mg once, twice a day, swallowed with warm water, taken on an empty stomach or with a medium or low fat diet. Dosage Advice: If you have renal insufficiency and have started dialysis or severe hepatic insufficiency, or if you are experiencing varying degrees of skin toxicity with sorafenib, you may need to adjust your dose, consult your doctor or pharmacist for details. Overdose manifestations and management: If you have overdosed on Sorafenib, you may experience diarrhea and other symptoms. There is no specific antidote for this drug, so avoid overdose. If you overdose with Sorafenib, please stop the drug immediately and go to a regular hospital. If you are taking the drug regularly as prescribed by your doctor and you miss a single dose before the next scheduled dose, you may take the drug immediately; if you miss a dose and it is almost time for the next scheduled dose, you do not need to take the drug. or as directed by your doctor ” tab_4_title=”Precautions” tab_4_content=”1. If you need to have major surgery while using Sorafenib, you will need to suspend the use of Sorafenib and consult your doctor when to restart the drug after the surgical wound has healed. 2. If you need live vaccinations such as rabies vaccine, BCG vaccine, etc., please wait until 3 months after you stop using Sorafenib. During this time, please avoid scratches and bites from dogs and cats. Increase or decrease discontinuation: After starting sorafenib, please take it until there is a worsening of the disease or a serious intolerable adverse reaction occurs. Sorafenib is a prescription drug and should be used in accordance with the dosage prescribed by your doctor. Any increase or decrease in dosage should be evaluated by your doctor and gradually increased or decreased under your doctor’s supervision. If it is necessary to discontinue the drug after the doctor’s evaluation, the dosage should be gradually reduced under the doctor’s guidance and eventually discontinued. Otherwise, adverse drug reactions may occur. ” tab_5_title=”Contraindications” tab_5_content=”Prohibited Information: With squamous cell lung cancer and in combination with carboplatin and paclitaxel. Severe hypersensitivity to sorafenib. Cautionary information: prolonged QT interval. Risk of QT interval prolongation due to congenital long QT syndrome or electrolyte disturbances. Supra-indication: 1. For recurrent or metastatic choroidal sarcoma. 2. For refractory gastrointestinal mesenchymal tumors. Only the supra-national indication with high evidence-based evidence is included; if you need to use it, please make sure you ask your doctor and pharmacist carefully.” tab_6_title=”Adverse Reactions” tab_6_content=”Emergency Discontinuation and Immediate Medical Attention: If you suddenly experience profuse sweating, difficulty breathing, severe chest pain, inability to lie down, severe abdominal pain, extensive skin ulceration or peeling, severe increase in blood pressure, or yellowing of the skin and eyes while taking the drug, you should stop the drug and seek immediate medical attention. hospital immediately. Adverse reactions: In the process of using drugs, in addition to treating your disease, the drug may also cause you some discomfort, which is an adverse drug reaction. Some of the adverse reactions may disappear in the course of drug use. When you encounter adverse reactions that affect your life, you should promptly communicate with your doctor and pharmacist Common: infection, anorexia, diarrhea, nausea, vomiting, constipation, blood in stool, high blood pressure, weakness, mouth pain, chest pain, bone pain, headache, hair loss, rash, itching, erythema, dry skin, tingling or burning sensation on the palms of hands and soles of feet, weight loss. Also when you have your blood drawn for testing you may also find: decreased lymphocytes, decreased blood phosphorus, increased blood amylase, and increased blood lipase. When using renal cell carcinoma or hepatocellular carcinoma, you may experience different degrees of skin toxicity. Once you experience the following symptoms, please inform your doctor or pharmacist promptly, they will give you appropriate measures according to the severity and frequency of your symptoms, such as symptomatic treatment, dose reduction, discontinuation of sorafenib or switching to other drugs, do not increase/decrease the dose, stop taking the drug or switch to other drugs on your own. If you experience paresthesia, dullness of sensation, abnormal sensation, numbness, painless swelling, erythema or discomfort in the hands and feet that does not interfere with daily activities, do not be alarmed as local symptomatic treatment can eliminate these symptoms and you can continue to use sorafenib. If you experience painful erythema and swelling and/or discomfort in the hands and feet that interfere with daily activities, continue to use the drug with topical treatment to eliminate the symptoms; if the symptoms do not improve within 7 days, or if they occur for the second or third time, you should discontinue sorafenib until the symptoms resolve. When restarting sorafenib, reduce the dose to 400 mg once a day; if the above symptoms occur for the 4th time, you should not continue using sorafenib. 3. If wet flaking, ulcers, blistering of the hands and feet, pain, or severe hand and foot discomfort that prevents you from working and living normally occurs on the first or second occasion, you should discontinue sorafenib until the symptoms resolve. When restarting sorafenib, reduce the dose to 400 mg once a day; do not continue sorafenib if you experience these symptoms for the 3rd time. If you experience any of the following symptoms, please inform your physician or pharmacist promptly. They will give you appropriate measures, such as symptomatic treatment, dose reduction or discontinuation of sorafenib, and dose increase according to the relief of symptoms. Do not reduce/increase the dose or stop the medication. 1. If you experience paresthesia, dullness, abnormal sensation, numbness, painless swelling, erythema or discomfort in the hands and feet that does not interfere with daily activities, there is no cause for alarm and you may continue to use sorafenib. 2. If erythema and swelling of the hands and feet with pain and/or discomfort in the hands and feet that interferes with daily activities occurs for the 1st time, you need to reduce the dose of sorafenib to 400 mg twice a day at 12-hour intervals and 200 mg once; if there is no improvement within 7 days or if it occurs for the 2nd or 3rd time, sorafenib should be suspended until the symptoms resolve. When restarting sorafenib, treatment should be at a reduced dose; consult your doctor or pharmacist for details; do not continue sorafenib if it occurs for the 4th time. 3. If you develop wet flaking, ulcers, blistering on the hands and feet, or severe pain that prevents you from working or going about your daily life, you will need to stop using sorafenib for the first two episodes until your symptoms resolve. When restarting sorafenib, reduce the dose during treatment and consult your doctor or pharmacist for details; do not continue using sorafenib if it occurs for the 3rd time. ” tab_7_title=”Interactions” tab_7_content=”Food: Foods high in fat can interfere with the absorption of sorafenib; foods low in fat have no effect. Medications: Avoid sorafenib if you are using rifampin, St. John’s Wort, phenytoin, carbamazepine, phenobarbital, dexamethasone, or rifabutin. If you are using docetaxel, doxorubicin, irinotecan, warfarin, please consult your doctor before using the drug and use sorafenib with caution under your doctor’s supervision. ” tab_8_title=”Special Populations” tab_8_content=”Pregnant/Nursing Elderly Infants Men Renal insufficiency Hepatic insufficiency ” tab_9_title=”Other” tab_9_content=”Drug properties Sorafenib tebucate tablets: red round tablets. Common specifications Sorafenib tebucate tablets: 0.2 g. Reference price 24192 RMB – 28229 RMB Storage method Keep sealed below 25°C. Please keep the medicine out of the reach of children. “][/otw_shortcode_tabslayout]